首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Tissue engineering of small-diameter vascular grafts by endothelial progenitor cells seeding heparin-coated decellularized scaffolds.
【24h】

Tissue engineering of small-diameter vascular grafts by endothelial progenitor cells seeding heparin-coated decellularized scaffolds.

机译:内皮祖细胞播种肝素涂层的脱细胞支架,对小直径血管移植物进行组织工程。

获取原文
获取原文并翻译 | 示例
           

摘要

Successful construction of a small-diameter bioartificial vascular graft remains a great challenge. This study reports on novel tissue engineering vascular grafts (TEVGs) constructed by endothelial progenitor cells and heparin-coated decellularized vessels (DV). The DVs were fabricated from canine carotid arteries with observable depletion of cellular components. After heparin coating, the scaffolds possessed excellent antithrombogeneity. Canine endothelial progenitor cells harvested from peripheral blood were expanded and seeded onto heparin-coated DVs and cocultured in a custom-made bioreactor to construct TEVGs. Thereafter, the TEVGs were implanted into the carotid arteries of cell-donor dogs. After 3 months of implantation, the luminal surfaces of TEVGs exhibited complete endothelium regeneration, however, only a few disorderly cells and thrombosis overlaid the luminal surfaces of control DVs grafts, and immunofluorescent staining showed that the seeded cells existed in the luminal sides and the medial parts of the explanted TEVGs and partially contributed to the endothelium formation. Specifically, TEVGs exhibited significantly smaller hyperplastic neointima area compared with the DVs, not only at midportion (0.64 +/- 0.08 vs. 2.13 +/- 0.12 mm(2) , p < 0.001), but also at anastomotic sites (proximal sites, 1.03 +/- 0.09 vs. 3.02 +/- 0.16 mm(2), p < 0.001; distal sites, 1.84 +/- 0.15 vs. 3.35 +/- 0.21 mm(2), p < 0.001). Moreover, TEVGs had a significantly higher patency rate than the DVs after 3 months of implantation (19/20 vs. 12/20, p < 0.01). Overall, this study provided a new strategy to develop small-diameter TEVGs with excellent biocompatibility and high patency rate.
机译:小直径生物人工血管移植物的成功构建仍然是一个巨大的挑战。这项研究报告了由内皮祖细胞和肝素涂层的脱细胞血管(DV)构建的新型组织工程血管移植物(TEVG)。 DVs是由犬的颈动脉制成,并具有可观察到的细胞成分消耗。肝素包被后,支架具有出色的抗血栓形成性。将从外周血中收集的犬内皮祖细胞扩增并接种到肝素包被的DV上,并在定制的生物反应器中共培养以构建TEVG。此后,将TEVGs植入细胞供体犬的颈动脉中。植入3个月后,TEVG的管腔表面显示出完整的内皮再生,但是,只有少量无序细胞和血栓形成覆盖了对照DV移植物的管腔表面,免疫荧光染色表明,接种的细胞存在于管腔的侧面和内侧。外植TEVG的一部分,部分促成内皮的形成。具体而言,TEVG不仅在中部(0.64 +/- 0.08 vs. 2.13 +/- 0.12 mm(2),p <0.001),而且在吻合部位(近端部位, 1.03 +/- 0.09 vs.3.02 +/- 0.16 mm(2),p <0.001;远端部位,1.84 +/- 0.15 vs. 3.35 +/- 0.21 mm(2),p <0.001)。此外,在植入3个月后,TEVG的通畅率明显高于DV(19/20对12/20,p <0.01)。总体而言,这项研究提供了一种新的策略,以开发具有出色的生物相容性和高通畅率的小直径TEVG。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号